-
Featured
Mindfulness-based Cognitive Therapy Shows Promise for Treating Depression in Chronically Ill Patients
Mass General researchers were part of the first group to investigate whether mindfulness-based cognitive therapy might relieve depression in people with chronic pain.
-
Featured
Women with Major Depression During Pregnancy Have High Rates of Recurrence During Their Child's Formative Years
Depression during pregnancy is highly likely to recur after delivery, Mass General researchers have determined. The finding implies that maternal depression is a major confounder when assessing the influence of prenatal antidepressant exposure on child neurodevelopment.
-
Featured
Effective Ketamine Dosages for Treatment-resistant Depression Identified
Ketamine has long been used as a general anesthetic, but more recent research has found it to be effective in rapidly relieving depression symptoms when given at low, subanesthetic doses. New research identifies two optimal dosages.
-
Q&A with Dr. Cristina Cusin: What to Know About Esketamine and Ketamine Treatment
The FDA recently approved Spravato, an intranasal form of esketamine for patients with treatment-resistant depression, which produces improvement hours to days after administration.
-
Ketamine Has Potential Utility for Treating Treatment-Resistant Anxious Depression
Unlike traditional antidepressants, ketamine may be similarly effective in both anxious and nonanxious patients with treatment-resistant depression, according to a secondary analysis of a randomized, controlled clinical trial.
-
Improving Depressive Symptoms and Neuromodulation Technology
Joan A. Camprodon, MD, PhD, is chief of Mass General's Division of Neuropsychiatry, director of the Transcranial Magnetic Stimulation (TMS) Clinical Service and director of the Laboratory for Neuropsychiatry & Neuromodulation. In this video, he discusses creating individualized treatments using TMS for patients with depression and using TMS to reduce suicide risk in other patients. He also discusses the use of transcranial direct current stimulation (tDCS) as a precognitive therapy to improve executive function in patients across the neurological and psychiatric spectrum.
Learn more about the Depression Clinical and Research Program
Depression contributors
-
Cristina Cusin, MD
Assistant Professor in Psychiatry, Staff Psychiatrist, Depression Clinical and Research Program
Recent Article
Q&A with Dr. Cristina Cusin: What to Know About Esketamine and Ketamine Treatment
-
David Mischoulon, MD, PhD
Director, Depression Clinical and Research Program
Recent Article
Mindfulness-based Cognitive Therapy Shows Promise for Treating Depression in Chronically Ill Patients
-
Maurizio Fava, MD
Director, Division of Clinical Research of the MGH Research Institute, Executive Vice Chair, Department of Psychiatry, Executive Director, MGH Clinical Trials Network & Institute (CTNI), Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
Recent Article
Clinical Trial Suggests New Combination Drug Targeting Opioid System May Relieve Major Depression Symptoms
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.Resource Links
